For research use only. Not for therapeutic Use.
Fedratinib hydrochloride hydrate（Cat No.:I015076）is a selective inhibitor of Janus kinase 2 (JAK2), primarily used for treating myelofibrosis, a type of bone marrow cancer. By targeting JAK2, this compound disrupts abnormal signaling pathways that contribute to disease progression and symptoms such as splenomegaly and anemia. Fedratinib has demonstrated significant efficacy in clinical trials, improving patient outcomes and quality of life. Its ability to modulate inflammatory responses and hematopoiesis positions it as a crucial therapeutic agent in managing myeloproliferative disorders, offering a targeted approach to treatment.
| Catalog Number | I015076 |
| CAS Number | 1374744-69-0 |
| Molecular Formula | C₂₇H₄₀Cl₂N₆O₄S |
| Purity | ≥95% |
| Target | Stem Cell/Wnt |
| IUPAC Name | N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide;hydrate;dihydrochloride e |
| InChI | InChI=1S/C27H36N6O3S.2ClH.H2O/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4;;;/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31);2*1H;1H2 |
| InChIKey | QAFZLTVOFJHYDF-UHFFFAOYSA-N |
| SMILES | CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4.O.Cl.Cl |
| Reference | [1]. Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20.<br>[2]. Geron I, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008 Apr;13(4):321-30. |
